News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
272,087 Results
Type
Article (14499)
Company Profile (122)
Press Release (257466)
Section
Business (91020)
Career Advice (501)
Deals (15798)
Drug Delivery (64)
Drug Development (38000)
Employer Resources (53)
FDA (6415)
Job Trends (6456)
News (155187)
Policy (14422)
Tag
Academia (519)
Alliances (23782)
Alzheimer's disease (374)
Approvals (6405)
Artificial intelligence (58)
Bankruptcy (143)
Best Places to Work (4515)
Biosimilars (41)
Biotechnology (54)
Breast cancer (40)
Cancer (304)
Career advice (442)
Cell therapy (45)
Clinical research (31438)
Collaboration (131)
Compensation (57)
COVID-19 (814)
C-suite (51)
Data (296)
Diabetes (49)
Diagnostics (1306)
Drug pricing (56)
Earnings (32442)
Employer resources (47)
Events (38704)
Executive appointments (148)
FDA (6581)
Funding (103)
Gene therapy (59)
GLP-1 (295)
Government (1347)
Healthcare (3989)
Infectious disease (832)
Inflammatory bowel disease (45)
Interviews (63)
IPO (6059)
Job creations (2115)
Job search strategy (404)
Layoffs (176)
Legal (3497)
Lung cancer (46)
Manufacturing (88)
Medical device (1383)
Medtech (1386)
Mergers & acquisitions (9770)
Metabolic disorders (157)
Neuroscience (470)
NextGen Class of 2024 (1766)
Non-profit (750)
Northern California (403)
Obesity (98)
Opinion (111)
Patents (51)
People (29372)
Pharmaceutical (64)
Phase I (8260)
Phase II (13379)
Phase III (11845)
Pipeline (140)
Podcasts (42)
Policy (45)
Postmarket research (1420)
Preclinical (3328)
Radiopharmaceuticals (119)
Rare diseases (85)
Real estate (2766)
Regulatory (10062)
Research institute (638)
Resumes & cover letters (60)
Southern California (406)
Startups (1733)
United States (4117)
Vaccines (124)
Weight loss (77)
Date
Today (67)
Last 7 days (348)
Last 30 days (1120)
Last 365 days (13213)
2024 (11580)
2023 (14944)
2022 (20525)
2021 (21359)
2020 (19943)
2019 (15835)
2018 (12486)
2017 (14318)
2016 (13551)
2015 (15910)
2014 (12856)
2013 (11017)
2012 (11877)
2011 (12344)
2010 (11338)
Location
Africa (329)
Arizona (41)
Asia (20176)
Australia (2593)
California (935)
Canada (565)
China (103)
Colorado (39)
Connecticut (39)
Europe (39384)
Florida (131)
Illinois (114)
Indiana (81)
Kansas (52)
Maryland (212)
Massachusetts (839)
Minnesota (50)
New Jersey (415)
New York (270)
North Carolina (276)
Northern California (403)
Pennsylvania (279)
South America (514)
Southern California (406)
Texas (125)
Washington State (68)
272,087 Results for "rock creek pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neurodegenerative disease
Scholar Rock’s Shares Soar 300% After Phase III Win in Spinal Muscular Atrophy
With Monday’s data from SAPPHIRE, Scholar Rock is building toward regulatory submissions for apitegromab in spinal muscular atrophy in the first quarter of 2025.
October 8, 2024
·
2 min read
·
Tristan Manalac
Business
Silver Creek Pharmaceuticals Appoints Mark Corrigan, M.D. As President
Silver Creek Pharmaceuticals, a clinical-stage biotechnology company focused on the selective targeting of naturally-occurring growth factors to promote cell survival and growth, has appointed Mark Corrigan, MD, as President.
February 12, 2024
·
3 min read
Kapoose Creek Bio announces advancement of potent compounds in neurology using AI-powered technology
Kapoose Creek Bio, a Vancouver-based biotechnology company leveraging AI for drug discovery from nature, announced the identification and advancement of two lead compounds with exciting potential in neurology, spanning indications in neurodegeneration and mental health.
May 30, 2024
·
3 min read
Press Releases
Scholar Rock to Participate in Upcoming Investor Conferences
November 1, 2024
·
2 min read
Press Releases
Kapoose Creek Bio Acquires Exclusive License to Adapsyn Bioscience’s World-Leading AI Technology for Drug Development
October 30, 2024
·
3 min read
Genetown
Scholar Rock to Participate in Upcoming Investor Conferences - May 20, 2024
Scholar Rock today announced that management will participate in the following upcoming investor conferences in June.
May 20, 2024
·
3 min read
Business
Burning Rock Reports First Quarter 2024 Financial Results
Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, reported financial results for the three months ended March 31, 2024.
May 29, 2024
·
16 min read
Genetown
Scholar Rock to Host Investor Day on May 22, 2024
Scholar Rock today announced it will host an Investor Day on Wednesday, May 22, 2024 beginning at 8:30 a.m. ET in New York City.
May 14, 2024
·
3 min read
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
Burning Rock Biotech Limited has recently announced a collaboration with Bayer to develop next-generation sequencing -based companion diagnostic assays, aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy.
May 30, 2024
·
1 min read
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
Burning Rock Biotech Limited announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC on May 30, 2024, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450.
June 3, 2024
·
3 min read
1 of 27,209
Next
